Top-News
Pharmazeutika USA

Neurocrine Biosciences Inc Aktie

Aktie
WKN:  900964 ISIN:  US64125C1099 US-Symbol:  NBIX
108,83 $
+2,24 $
+2,10%
96,101 € 17:34:11 Uhr
Depot/Watchlist
Aktienanzahl *
100,98 Mio.
Marktkapitalisierung *
9,60 Mrd. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 10.10.2024

Neurocrine Biosciences Inc News

30.04.25 - PR Newswire
Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia
Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia PR Newswire
24.04.25 - PR Newswire
Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia in The Journal of Clinical Psychiatry
Neurocrine Biosciences Publishes Analysis Showing Long-Term Efficacy and a Consistent Safety Profile of INGREZZA® (valbenazine) Capsules in Older Adults with Tardive ...
14.04.25 - PR Newswire
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2025 Financial Results PR Newswire
04.04.25 - PR Newswire
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer
Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer PR Newswire
31.03.25 - PR Newswire
Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia
Neurocrine Biosciences Presents Real-​World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia PR Newswire
20.03.25 - PR Newswire
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules PR Newswire
17.03.25 - PR Newswire
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules PR Newswire
11.03.25 - PR Newswire
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum
Neurocrine Biosciences to Present at the Stifel 2025 Virtual CNS Forum PR Newswire
05.03.25 - PR Newswire
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-​Generation VMAT2 Inhibitor, in Healthy Adults PR Newswire
27.02.25 - PR Newswire
Neurocrine Biosciences Reports Patient-Reported Outcome Data from KINECT-PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically Meaningful Improvements in Functionality and Quality of Life Measures
Neurocrine Biosciences Reports Patient-​Reported Outcome Data from KINECT-​PRO™ Study for INGREZZA® (valbenazine) Capsules in Tardive Dyskinesia: Significant and Clinically ...
25.02.25 - PR Newswire
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March PR Newswire
21.02.25 - PR Newswire
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program
Neurocrine Biosciences Board of Directors Authorizes $500 Million Share Repurchase Program PR Newswire
10.02.25 - Wikifolio
Die heißesten Aktien der letzten Woche
Hier erfährst du, welche Aktien letzte Woche besonders oft ge- oder verkauft wurden und welche Motive dafür entscheidend waren.
10.02.25 - Der Aktionär
Neurocrine: Crash nach Zahlen – Einstiegschance?
06.02.25 - PR Newswire
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025
Neurocrine Biosciences Reports Fourth Quarter and Fiscal 2024 Financial Results and Provides Financial Expectations for 2025 PR Newswire
04.02.25 - Der Aktionär
AKTIONÄR‑Top‑Tipp Neurocrine: Kursziel rauf – diese Woche zählt es!
30.01.25 - PR Newswire
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2024 Financial Results PR Newswire
28.01.25 - PR Newswire
Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults
Neurocrine Biosciences Announces Initiation of Phase 3 Registrational Program for Osavampator as an Adjunctive Therapy for the Treatment of Major Depressive Disorder in Adults ...
27.01.25 - PR Newswire
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653)
Neurocrine Biosciences Announces Amendment to Strategic Collaboration with Takeda to Develop and Commercialize Osavampator (formerly NBI-1065845/TAK-653) PR Newswire
23.01.25 - PR Newswire
Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device
Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device PR Newswire

Newssuche

Videos

newspaper
30.04.25 +13,48%
Technical Trading: Cotton Long Chance
Cotton Long Typ: Turbo Open End WKN: VP6N8D Hebel: 3,80 Laufzeit: OpenEnd Einstieg: Market ... Mehr »